Department of foundation courses, Anhui Medical College, Hefei, China.
Artif Cells Nanomed Biotechnol. 2020 Dec;48(1):933-938. doi: 10.1080/21691401.2020.1773483.
miR-4293 rs12220909 polymorphism was reported associated with tumorigenesis, but the results are controversial. Thus, we planned to verify and obtain precise results. Databases were searched and reviewed up to November, 2019. Case-control studies which concern about the association between cancer risks and miR-4293 polymorphisms were all enrolled. The odds ratios (ORs) and 95% confidence intervals (CIs) calculated by the Z test were used to assess the underlying links. We also prospected how the miR-4293 impacts biological process through its target genes. Finally, there are seven independent studies meet the enrolled criteria, along with 5147 cases and 6108 healthy controls. We revealed that there is a significant decrease effect of miR-4293 rs12220909 to cancer risks in heterozygote genetic model (BA vs. AA: OR = 0.857, = .032), the similar results were also uncovered in PB control group, lung cancer and the studies conform to HWE. Results from GO items and KEGG pathway analysis illustrated that myeloid cell development, transcription factor complex, RNA polymerase II regulatory region DNA binding were regulated by miR-4293. In summary, our meta-analysis chase down heterozygote rs12220909 polymorphism of miR-4293 is a protective factor to cancer initiation, especially for lung cancer.
miR-4293 rs12220909 多态性被报道与肿瘤发生有关，但结果存在争议。因此，我们计划进行验证并获得更准确的结果。我们检索并回顾了截至 2019 年 11 月的数据库。所有涉及 miR-4293 多态性与癌症风险之间关联的病例对照研究都被纳入。使用 Z 检验计算的比值比 (OR) 和 95%置信区间 (CI) 用于评估潜在的联系。我们还预测了 miR-4293 通过其靶基因如何影响生物过程。最后，有 7 项独立研究符合纳入标准，共纳入 5147 例病例和 6108 例健康对照。我们发现 miR-4293 rs12220909 杂合基因型 (BA 与 AA：OR = 0.857，=.032) 对癌症风险有显著降低作用，PB 对照组、肺癌和符合 HWE 的研究也得到了类似的结果。GO 项和 KEGG 通路分析的结果表明，miR-4293 调节髓样细胞发育、转录因子复合物、RNA 聚合酶 II 调节区 DNA 结合。总之，我们的荟萃分析表明，miR-4293 的杂合 rs12220909 多态性是癌症发生的保护因素，特别是对肺癌。
